These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings

Abbott Laboratories (NYSE:ABT) reported better-than-expected third-quarter results on Wednesday.

The company posted sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Abbott’s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.

"Our results this quarter demonstrate the strength of our diversified business model," said Robert Ford, chairman and CEO of Abbott. "We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year."

Abbott projects full-year 2024 adjusted ...

Full story available on Benzinga.com